RNS Number : 3080L
Abingdon Health PLC
04 June 2025
 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Update re. strategic partnership with Find Out From Home LLC

 

York, U.K. 4 June 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that Chris Yates, President of Abingdon Health Inc., has been appointed as a Director of US-based Find Out From Home LLC ("FOFH").

 

Abingdon Health retains a 19% shareholding in FOFH, through a service-for-equity arrangement. On 25 March 2024 (RNS 9783H), Abingdon Health announced its strategic partnership with FOFH followed by another announcement on 17 December 2024 (RNS 3086Q), confirming that it had entered into a contract worth a total of US$2million with FOFH regarding the performance evaluation, regulatory services and clinical testing of four sexually transmitted disease ("STD") tests.

 

The Company continues to work with FOFH, on the regulatory approval of their first four STD self-tests and the development of a further three STD tests.

 

Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Hand, Executive Chairman

 

Via Walbrook PR

Tom Hayes, CFO

 




Zeus (Sole Broker and Nominated Adviser)

  Tel: +44 (0)20 3829 5000

Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance)


Fraser Marshall (Corporate Broking)

 

 

 



Walbrook PR (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.

 

The Company's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUOOORVUUNRUR